SCG Cell Therapy receives FDA IND clearance for HPV-specific TCR T cell therapy SCG142 for HPV-associated solid tumors.
SCG Cell Therapy announces FDA IND clearance for SCG142, a next-generation HPV-specific TCR T cell therapy for patients with HPV-associated solid tumors. This marks the advancement of the company's TCR-based therapeutic program to treat unmet needs in major cancer indications. The novel therapy candidate is generated from SCG's proprietary GianTCRTM platform, and SCG is ready to commence multi-center Phase 1/2 clinical trials.
July 01, 2024
3 Articles